Argenx also announced preliminary global net Vyvgart revenues for the fourth quarter and full-year 2022 of approximately $175M and $402M, respectively. As of December 31, 2022, argenx had approximately $2.2B in cash, cash equivalents and current financial assets*. Based on its current operating plans and a projected 2023 cash burn of approximately $500M, Argenx expects its existing cash, cash equivalents and current financial assets, together with anticipated future product revenues, to fund the company to profitability.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- Argenx price target raised to EUR 500 from EUR 480 at JPMorgan
- Argenx included on Wells Fargo’s Tactical Ideas List for Q1 2023
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
